Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears

November 9, 2026 updated by: Esra Ülgen Kıratlıoğlu, Ankara City Hospital Bilkent

Intralesional Versus Perilesional 5% Dextrose Injection for Partial Supraspinatus Tendon Tears: A Randomized Controlled Trial

This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).

Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.

Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.

Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.

Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ankara, Turkey (Türkiye)
        • Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 to 75 years
  • Shoulder pain and functional limitation for at least 3 months
  • Partial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
  • At least one positive Neer, Hawkins-Kennedy, or painful arc test
  • Ability to attend follow-up visits
  • Written informed consent to participate

For participants with bilateral involvement, only the more painful shoulder was included.

Exclusion Criteria:

  • - Full-thickness supraspinatus tendon tear
  • Major pathology of rotator cuff tendons other than the supraspinatus
  • Advanced acromioclavicular or glenohumeral osteoarthritis
  • Marked adhesive capsulitis
  • Previous shoulder surgery
  • Corticosteroid, platelet-rich plasma, or prolotherapy injection into the affected shoulder within the previous 3 months
  • Active infection, including infection at the injection site
  • Skin lesion at the injection site
  • Bleeding diathesis or anticoagulant use
  • Known allergy or intolerance to dextrose
  • Uncontrolled diabetes mellitus (HbA1c >8.5%)
  • Severe endocrine or metabolic disease
  • Immunosuppression
  • Rheumatologic disease involving the shoulder
  • Neurological disease affecting shoulder function
  • Pregnancy
  • Active malignancy
  • Cognitive impairment preventing reliable completion of questionnaires

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intralesional 5% Dextrose Injection

Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection.

At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session.

Active Comparator: Perilesional 5% Dextrose Injection

Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection.

At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
Time Frame: Baseline and study weeks 9 and 12.

Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity.

Baseline and study weeks 9 and 12.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
Time Frame: Baseline and study weeks 9 and 12.

The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability.

Baseline and study weeks 9 and 12.
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
Time Frame: Baseline and study weeks 9 and 12.

Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component.

Baseline and study weeks 9 and 12.
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
Time Frame: Baseline and study week 12.

Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer.

Baseline and study week 12.
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
Time Frame: Baseline and study week 12.

The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect.

Baseline and study week 12.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: ESRA Ülgen Kıratlıoğlu, Ankara City Hospital Bilkent

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2025

Primary Completion (Actual)

February 1, 2026

Study Completion (Actual)

February 1, 2026

Study Registration Dates

First Submitted

June 30, 2026

First Submitted That Met QC Criteria

June 30, 2026

First Posted (Actual)

July 7, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • E2-26-14590

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to privacy and ethical restrictions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.